- 1 Appendix Table 1. Median anti–SARS-CoV-2 serum antibody titers and ratios post-vaccination and
- 2 post-infection by isotype among participants (N=11) in a nursing home cohort—Georgia, October

3 2020-April 2021*

	Post-infection		Post-vaccination		Ratio post-
Time period (days)	No.	Median titer (IOR) [†]	No.	Median titer	vaccination to post-
(44,5)	tested		tested		infection
Pan-Ig					
0–14	5	286 (257–1803)	9	5137 (3584–73070)	18.0
15–30	7	1,441 (1289–3682)	8	299,721 (240573–345136)	208.0
31–60	9	4,769 (2832–7582)	9	64,344 (55171–127753)	13.5
61–90	3	4,763 (2832–6153)	4	53,664 (38454–71967)	11.3
lgG					
0–14	5	395 (298–3340)	9	11,758 (5797–25900)	29.8
15–30	7	3,563 (2662–8028)	8	206,062 (95411–1258378)	57.8
31–60	9	7,472 (4952–15971)	9	380,248 (318681–8705015)	50.9
61–90	3	6,973 (6495–7217)	4	130,964 (73799–185779)	18.8
lgA					
0–14	3	155 (134–223)	3	399 (288–645)	2.6
15–30	7	318 (277–697)	8	2,777 (1178–4462)	8.7
31–60	7	198 (154–1255)	9	1,956 (754–4242)	9.9
61–90	3	399 (379–445)	4	656 (272–1742)	1.6

4 Abbreviations: IQR = interquartile range

5 ^{*}The post-infection period was defined as the time from SARS-CoV-2 diagnosis (by BinaxNOW[™] COVID-

6 19 Ag Cards and/or real-time reverse transcription polymerase chain reaction) to receipt of first Pfizer-

7 BioNTech COVID-19 Vaccine dose. The post-vaccination period was defined as the time after receipt of

8 first vaccine dose to the end of the evaluation period. Individuals with serum antibody titers below the

9 seroconversion threshold (defined as a signal threshold >1 at the 1:100 dilution for any isotype) were

10 not included in median and ratio calculations.

⁺ Median post-infection titers peaked during 15–30 days for IgM, 31–60 days for Pan-Ig and IgG, and 61–

12 90 days for IgA.

- ¹³ [‡] Participant C was not included in the post-vaccination analyses due to vaccination refusal. This
- participant's titers ranged from 2437–16977 for Pan-Ig, 4919–7045 for IgG, and 267–710 for IgA during
- 15 the 90–150 days post-infection; their IgM titers were below the limit of detection during this time
- 16 period.
- [§] Median post-vaccination titers peaked during 15–30 days for Pan-Ig and IgA, and 31–60 days for IgG.
- 18 Post-vaccination median IgM titers were not calculated because most post-vaccination titers were
- 19 below the limit of detection.

Appendix Figure 1. Detection of SARS-CoV-2 by BinaxNOW[™] rapid antigen test, real-time reverse
 transcription polymerase chain reaction, and viral culture by Pan-Ig serum antibody titers and days
 post-diagnosis of participants (N=11) in a nursing home cohort—Georgia, October 2020–April 2021



24 Abbreviations: BinaxNOW = BinaxNOW[™] COVID-19 Ag Card; RT-PCR = real-time reverse transcription

25 polymerase chain reaction; Cx = viral culture

Blood samples were obtained at several timepoints between 1–150 days post-diagnosis (time period
after each participant's first positive SARS-CoV-2 test result). Due to challenges phlebotomizing some
participants, serum titers were not generated for each participant for each visit. Participants with serum
antibody titers below the seroconversion threshold (defined as a signal threshold >1 at the 1:100
dilution for any isotype) were assigned a value of 25 for graphical representation only. The y-axis is
plotted in logarithmic scale.

```
    Appendix Figure 2. Anti–SARS-CoV-2 serum antibody titers by isotype and days post-diagnosis among
    participants (N=11) in a nursing home cohort—Georgia, October 2020–April 2021
```



35 Colored lines represent individual participants. Blood samples were obtained at several timepoints 36 between 1–150 days post-diagnosis (time period after each participant's first positive SARS-CoV-2 test 37 result). Due to challenges phlebotomizing some patients, serum titers were not generated for each 38 participant for each visit. Pfizer-BioNTech COVID-19 vaccines were administered at the facility between 39 71–105 days post-diagnosis; participant C declined vaccination. Participants with serum antibody titers 40 below the seroconversion threshold (defined as a signal threshold >1 at the 1:100 dilution for any isotype) were assigned a value of 25 for graphical representation only. The y-axis is plotted in 41 42 logarithmic scale.

Appendix Figure 3. Anti–SARS-CoV-2 serum antibody titers by isotype and detection of SARS-CoV-2 by
 BinaxNOW[™] rapid antigen test, real-time reverse transcription polymerase chain reaction, and viral
 culture post-diagnosis, by participant (N=11) in a nursing home cohort—Georgia, October 2020–April
 2021

Titer

Ct value











Days post-diagnosis

Days post-diagnosis

48 Abbreviations: BinaxNOW = BinaxNOW[™] COVID-19 Ag Card; RT-PCR = real-time reverse transcription

49 polymerase chain reaction; Cx = viral culture

Blood samples were obtained at several timepoints between 1–150 days post-diagnosis (time period after each participant's first positive SARS-CoV-2 test result). Due to challenges phlebotomizing some patients, serum titers were not generated for each participant for each visit. Pfizer-BioNTech COVID-19 vaccines were administered at the facility between 71–105 days post-diagnosis; participant C declined vaccination. Participants with serum antibody titers below the seroconversion threshold (defined as a signal threshold >1 at the 1:100 dilution for any isotype) were assigned a value of 25 for graphical representation. The y-axis is plotted in logarithmic scale.